Omnicell, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Omnicell, Inc. on September 25, 2024. The filing reports the appointment of a new executive officer effective October 7, 2024. Omnicell is a Delaware corporation with its principal executive offices in Fort Worth, Texas, and its common stock trades on the NASDAQ Global Select Market under the symbol OMCL.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Nnamdi Njoku as Executive Vice President and Chief Operating Officer. Mr. Njoku joins from Zimmer Biomet Holdings, Inc., where he served as President of Sports Medicine, Surgical, Upper Extremities, and Restorative Therapies. Prior to that, he held various executive roles at Medtronic, Inc.
Compensation and Management Commentary
Mr. Njoku's compensation package includes the following components:
- Base Salary: $645,000 per annum.
- Special Cash Bonus: Target of $161,250 for the fourth quarter, subject to onboarding and assimilation goals.
- Annual Cash Bonus: Target of 100% of base salary under the Executive Bonus Plan, based on financial results and incentive goals.
- One-Time Equity Award: Approximately $2,250,000 in Restricted Stock Units (RSUs). Vesting schedule: 25% on November 15, 2025, and the remaining 75% in equal quarterly installments over the subsequent three years.
- 2025 Annual Equity Award:
- RSUs with a grant date value of approximately $1,500,000, vesting over four years.
- Performance-Based Restricted Stock Units (PSUs) with a grant date value of approximately $1,500,000. Payout ranges from 0% to 200% based on relative total stockholder return over one year.
- Benefits: Eligibility for severance benefits, indemnity protection, perquisites (financial planning, physicals), and standard employee health and welfare plans.
The filing states there are no family relationships between Mr. Njoku and any director or executive officer, and no other arrangements requiring disclosure under Item 404 of Regulation S-K.
Investor Verification Checklist
- Verify the effective start date of October 7, 2024, for the new COO.
- Review the specific vesting schedules and performance metrics for the $1.5 million PSU award.
- Confirm the total potential equity value ($5.25 million in grant date value) relative to the company's current stock price.
- Check the upcoming Form 10-Q for the period ending September 30, 2024, for the attached offer letter exhibit.